Talent Testing Service (TTS), releases its February 2026 update featuring the latest positivity rates of Sexually Transmitted Diseases (STDs).
Chlamydia Urine - Positivity Index
Overall, the three Chlamydia Urine rates show a similar behavior through time including the steady downward trend from the November 2022 peak. In February 2026 the Total and Male rates dropped from 1.1% to 0.7% and 0.9% respectively, and the Female rate also is down from 1.2% to 0.4%. Seeing that historic levels have been around 2.0%, the current rates being below 2.0% can be considered to be within expectations.
GC (Gonorrhea) Urine - Positivity Index
In February 2026 the three Gonorrhea Urine rates decreased to 0.2%, the Total rate from 0.4%, the Male from 0.3%, and the Female rate from 0.6%. In this month the three rates continue the linear trend.
Trichomonas Vaginalis Urine- Positivity Index
In February 2026 two of the Trichomonas Vaginalis Urine rates increased, the Total rate to 0.4% from 0.3%, and the Female rate to 0.8% from 0.5%; the Male rate dipped to 0.1% from 0.2%. The current rate levels are still within the general range of 0.0% to 1.5%.
Mycoplasma Genitalium Urine - Positivity Index
In February 2026, as in the prior month, all the Mycoplasma G. Urine rates increased, the Female rate to 4.9% from 3.4%, the Total rate to 4.3% from 2.8%, and the Male rate to 3.8% from 2.3%.
Chlamydia & GC (Gonorrhea) Throat and Rectal Swabs - Positivity Index
Based on market activity, the positivity rates for the four tests below have December 2022 as a relevant, starting point where all levels display their peak and then start overall downward trends. In February 2026, two Chlamydia Rectal rates increased again, the Total rate to 1.7% from 1.5% and the Female rate to 2.1% from 1.8%, while the Male rate turned down to 1.2% from 1.3%. The three Chlamydia Throat rates decreased, the Total rate to 0.2% from 0.5%, the Male rate to 0.1% from 0.3%, and the Female rate to 0.3% from 0.7%. Although within an overall smaller range of 0.0% to 3.5%, when compared to the other swab rates, the volatility of the Gonorrhea Rectal lines is visible since April 2023, showing increase in February 2026 for the three rates, the Female rate to 0.6% from 0.5%, the Male rate to 1.3% from 0.4%, and the Total rate to 1.0% from 0.4%. The Gonorrhea Throat rates have two unchanged, the Total rate at 0.8% and the Male rate at 0.6%, while the Female rate is up to 1.1% from 1.0%.
Chlamydia Urine - Positivity Index
Overall, the three Chlamydia Urine rates show a similar behavior through time including the steady downward trend from the November 2022 peak. In February 2026 the Total and Male rates dropped from 1.1% to 0.7% and 0.9% respectively, and the Female rate also is down from 1.2% to 0.4%. Seeing that historic levels have been around 2.0%, the current rates being below 2.0% can be considered to be within expectations.
GC (Gonorrhea) Urine - Positivity Index
In February 2026 the three Gonorrhea Urine rates decreased to 0.2%, the Total rate from 0.4%, the Male from 0.3%, and the Female rate from 0.6%. In this month the three rates continue the linear trend.
Trichomonas Vaginalis Urine- Positivity Index
In February 2026 two of the Trichomonas Vaginalis Urine rates increased, the Total rate to 0.4% from 0.3%, and the Female rate to 0.8% from 0.5%; the Male rate dipped to 0.1% from 0.2%. The current rate levels are still within the general range of 0.0% to 1.5%.
Mycoplasma Genitalium Urine - Positivity Index
In February 2026, as in the prior month, all the Mycoplasma G. Urine rates increased, the Female rate to 4.9% from 3.4%, the Total rate to 4.3% from 2.8%, and the Male rate to 3.8% from 2.3%.
Chlamydia & GC (Gonorrhea) Throat and Rectal Swabs - Positivity Index
Based on market activity, the positivity rates for the four tests below have December 2022 as a relevant, starting point where all levels display their peak and then start overall downward trends. In February 2026, two Chlamydia Rectal rates increased again, the Total rate to 1.7% from 1.5% and the Female rate to 2.1% from 1.8%, while the Male rate turned down to 1.2% from 1.3%. The three Chlamydia Throat rates decreased, the Total rate to 0.2% from 0.5%, the Male rate to 0.1% from 0.3%, and the Female rate to 0.3% from 0.7%. Although within an overall smaller range of 0.0% to 3.5%, when compared to the other swab rates, the volatility of the Gonorrhea Rectal lines is visible since April 2023, showing increase in February 2026 for the three rates, the Female rate to 0.6% from 0.5%, the Male rate to 1.3% from 0.4%, and the Total rate to 1.0% from 0.4%. The Gonorrhea Throat rates have two unchanged, the Total rate at 0.8% and the Male rate at 0.6%, while the Female rate is up to 1.1% from 1.0%.
